Valganciclovir Powder, For Solution
NDC Package 42571-477-47
Package Information
Valganciclovir powders is valganciclovir for oral solution is contraindicated in patients who have had a demonstrated clinically significant hypersensitivity reaction (e.g., anaphylaxis) to valganciclovir, ganciclovir, or any component of the formulation [see Adverse Reactions ( 6.1)]. This formulation utilizes a powder, for solution delivery system. Marketed by Micro Labs Limited, this product is identified by NDC 42571-477 and is authorized under FDA application ANDA218838.
Identification & Billing
- RxCUI: 863559 - valGANciclovir 50 MG in 1 mL Oral Solution
- RxCUI: 863559 - valganciclovir 50 MG/ML Oral Solution
- RxCUI: 863559 - valganciclovir (as valganciclovir hydrochloride) 50 MG/ML Oral Solution
- RxCUI: 863559 - valganciclovir 50 MG per 1 ML Oral Solution
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 42571 - Micro Labs Limited
- 42571-477 - Valganciclovir
- 42571-477-47 - 1 BOTTLE in 1 CARTON / 100 mL in 1 BOTTLE
- 42571-477 - Valganciclovir
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 42571-477-47 identifies a specific commercial package of 1 bottle in 1 carton / 100 ml in 1 bottle of Valganciclovir, a human prescription drug labeled by Micro Labs Limited. This powder, for solution is formulated for oral use and contains valganciclovir hydrochloride as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Micro Labs Limited on June 01, 2026. The current certification is valid through December 31, 2027.
How is this Micro Labs Limited product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 42571047747. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.